About Us >> Founder

Lieping Chen, M.D., Ph.D.

Dr. Lieping Chen is the United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology) at Yale University.  He is also the Co-Director of the Cancer Immunology Program at Yale Cancer Center.  Dr. Chen is a pioneer in the field of lymphocyte co-stimulation and co-inhibition.  In 1992, Dr. Chen was the first to discover “co-stimulation of tumor immunity” and use co-stimulatory molecules to treat cancer and other diseases.  Since then, his laboratory has identified and characterized various molecules in the B7-CD28 and the TNF receptor/ligand super families, elucidating their interactions and functions in the control of immune responses.  His laboratory first cloned B7-H1 (PD-L1), discovered its immune suppressive functions, and invented the principles behind modulating immune responses that target the PD-1/B7-H1 pathway to treat advanced stages of human cancers.  Dr. Chen has authored 200+peer-reviewed articles and delivered more than 200 lectures, seminars and keynote speeches internationally.

Dr. Chen earned his medical degree from Fujian Medical School in Fuzhou City, China in 1982, and completed his clinical training in hematology and oncology at Fujian Union Hospital in Fuzhou and Beijing Union Medical College Cancer Hospital in Beijing, China before earning his Ph.D. in pathology from Drexel University in Philadelphia, Pennsylvania in 1989. After a postdoctoral fellowship at the University of Washington in Seattle, Washington he worked at Bristol-Myers Squibb as a research scientist from 1990-1997, and was recruited by the Mayo Clinic in Rochester, Minnesota where he was promoted to the rank of Professor by 2000. In 2004, he joined the faculty at Johns Hopkins University School of Medicine in Baltimore, Maryland as a Professor of Oncology & Dermatology and the Director of Research in Dermatology prior to assuming his current position at Yale University in New Haven, Connecticut in 2010.